Physician profile
Shayna B Burke
NPI 1609078708
$26,052.02
in general payments reported to CMS, 2019-2025
15 companies · $6,657 in 2025
The $6,657 reported for 2025 was more than what 89% of Clinical & Laboratory Immunology (Allergy & Immunology) providers received nationally (typical 2025 total: $1,390).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,828 · 2021: $2,683 · 2022: $467 · 2023: $518 · 2024: $1,217 · 2025: $6,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,280 · Food and Beverage: $2,680 · Travel and Lodging: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,280.00 |
| Food and Beverage | $2,680.39 |
| Travel and Lodging | $431.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $13,312.78 | 2019-2021 | |
| Biocryst Pharmaceuticals, INC. | $6,021.52 | 2020-2025 | Orladeyo |
| Biocryst US Sales Co., LLC | $1,804.53 | 2023-2025 | Orladeyo |
| Alk-Abello, INC | $1,504.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $1,493.21 | 2019-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $569.89 | 2019-2021 | |
| Amgen INC. | $390.34 | 2022-2024 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $287.15 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $256.23 | 2019-2025 | Nucala |
| Genzyme Corporation | $219.52 | 2020-2025 | |
| Grifols USA, LLC | $89.07 | 2020 | |
| Pfizer INC. | $34.95 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $26.65 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $22.22 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shayna Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.